A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
Latest Information Update: 05 Apr 2022
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Eisai Inc
- 10 Dec 2019 Results of post-hoc analysis assessing safety data from Study 402 by perampanel dose at onset of the TEAE, and the presence or absence of an enzyme-inducing ASD (EIASD). presented at the 73rd Annual Meeting of the American Epilepsy Society
- 05 Sep 2018 Status changed from recruiting to completed.
- 23 Aug 2014 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network